נזילות מהירה Coeptis Therapeutics (COEP)

Coeptis Therapeutics (COEP) is developing innovative methods to combat blood cancers. The price trend illustrates a business model where clinical trials and drug production are fully outsourced to third-party contractors. Simultaneously, the company is diversifying its portfolio by creating various immune activation platforms. The current metric stands at 4.01, while financial stability remains limited by a dependence on venture capital investments and the pace of preclinical testing.

The quick ratio measures a business's ability to instantaneously cover short-term liabilities using cash and accounts receivable, completely ignoring low-liquidity inventory. For Coeptis Therapeutics (COEP), which is expanding through academic partnerships and licensing, the recorded quick ratio serves as an indicator of the startup's financial viability in the absence of M&A activity and its dependence on the pace of laboratory research.